Cargando…

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

BACKGROUND: We examined the impact of race on the maximum tolerated doses (MTD) and final approved doses (FAD) of single-agent molecular-targeted agents (MTA) in North America/Europe (NA/EU) and Asia. METHODS: We searched PubMed and regulatory databases to identify targeted drugs approved globally a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokota, Tomoya, Bendell, Johanna, LoRusso, Patricia, Tsushima, Takahiro, Desai, Ved, Kenmotsu, Hirotsugu, Watanabe, Junichiro, Ono, Akira, Murugesan, Bhavani, Silva, Joseph, Naito, Tateaki, Greenberg, Jonathan, Kumar, Prasanna, Wang, Yibin, Jikoh, Takahiro, Shiga, Ryota, Hyman, David M., Ho, Alan Loh, Spriggs, David R., Schwartz, Gary K., Gounder, Mrinal M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008299/ https://www.ncbi.nlm.nih.gov/pubmed/29795308 http://dx.doi.org/10.1038/s41416-018-0102-1

Ejemplares similares

Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer
por: Mayanagi, Shuhei, et al.
Publicado: (2017)

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
por: Hyman, David M., et al.
Publicado: (2015)

Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non‐small cell lung cancer
por: Harada, Hideyuki, et al.
Publicado: (2016)

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
por: Shitara, Kohei, et al.
Publicado: (2020)

Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study
por: Mitsuya, Koichi, et al.
Publicado: (2019)

Acquired immunodeficiency associated with thymoma: a case report
por: Kawamura, Takahisa, et al.
Publicado: (2019)

The effects of advanced age and serum α(1)‐acid glycoprotein on docetaxel unbound exposure and dose‐limiting toxicity in cancer patients
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2017)

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
por: Ono, Akira, et al.
Publicado: (2013)

Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy
por: Kobayashi, Haruki, et al.
Publicado: (2018)

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
por: Kawamura, Takahisa, et al.
Publicado: (2019)

Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities
por: Kobayashi, Haruki, et al.
Publicado: (2021)

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
por: Mamesaya, Nobuaki, et al.
Publicado: (2023)

Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter
por: Watanabe, Masaru, et al.
Publicado: (2018)

Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure
por: Kawamura, Takahisa, et al.
Publicado: (2016)

Days Spent at Home near the End of Life in Japanese Elderly Patients with Lung Cancer: Post hoc Analysis of A Prospective Study
por: Notsu, Mikako, et al.
Publicado: (2021)

Evaluation of the True Endpoint of Clinical Trials for Cancer Cachexia
por: Naito, Tateaki
Publicado: (2019)

Emerging Treatment Options For Cancer-Associated Cachexia: A Literature Review
por: Naito, Tateaki
Publicado: (2019)

Nursing Management of Cancer Cachexia: A New Frontier
por: Naito, Tateaki
Publicado: (2021)

Challenges in enhancing physical performance in thoracic cancer cachexia
por: Naito, Tateaki
Publicado: (2021)

Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy
por: Kasahara, Norimitsu, et al.
Publicado: (2015)

Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Primary malignant melanoma of the trachea: A case report
por: IMAI, HISAO, et al.
Publicado: (2015)

Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2015)

Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis
por: Takinami, Masaki, et al.
Publicado: (2021)

Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2021)

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients
por: Ko, Ryo, et al.
Publicado: (2016)

Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2020)

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
por: Kodama, Hiroaki, et al.
Publicado: (2021)

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2015)

Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer
por: Inoue, Hiroto, et al.
Publicado: (2020)

Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
por: Miyawaki, Taichi, et al.
Publicado: (2020)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Miyawaki, Taichi, et al.
Publicado: (2021)

Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer
por: Yonenaga, Yusuke, et al.
Publicado: (2021)

Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2022)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy
por: Imai, Hisao, et al.
Publicado: (2015)

Reduced ER-mitochondrial contact sites and mitochondrial Ca(2+) flux in PRKN-mutant patient tyrosine hydroxylase reporter iPSC lines
por: Yokota, Mutsumi, et al.
Publicado: (2023)

Barriers in Nursing Practice in Cancer Cachexia: A Scoping Review
por: Sato, Rika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mlis2lj37g3kds1coo0l265c5s